🇺🇸 FDA
Patent

US 10696710

Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

granted A61KA61K2039/55511A61K2039/55561

Quick answer

US patent 10696710 (Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway) held by The Board of Regents of the University of Texas System expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/55511, A61K2039/55561, A61K31/7084, A61K39/39